) recently announced that gabapentin enacarbil, which is the
active ingredient in Horizant, has been included in an updated
treatment algorithm as an initial therapy for patients with
chronic persistent restless legs syndrome/Willis-Ekbom disease
(RLS/WED). The Wed Foundation's algorithm was published in the
current Mayo Clinic Proceedings issue.
Horizant is approved in the U.S. for the treatment of
moderate-to-severe primary restless legs syndrome (RLS) as well
as the management of postherpetic neuralgia (PHN) in adults.
In Jul 2013, Horizant was also included by the Task Force of the
International Restless Legs Syndrome Study Group in their new
treatment guidelines as a first-line treatment for RLS/WED. The
guidelines bode well for Horizant.
In May 2013, XenoPort resumed the supply and shipment of
Horizant. The company was also successful in resolving
manufacturing issues and expects to fill in orders from
wholesalers. We note that
) faced manufacturing delays of Horizant in the U.S., leading to
We remind investors that Glaxo and XenoPort had a collaboration
agreement for Horizant that was terminated in Nov 2012. Glaxo had
commercialization rights to the drug through the transition
period, which ended on Apr 30, 2013. On May 1, 2013, XenoPort
re-acquired all commercialization rights to Horizant. Glaxo,
however, is expected to supply Horizant to XenoPort until Oct 30,
XenoPort carries a Zacks Rank #3 (Hold). Currently, companies
which look attractive include
) with a Zacks Rank #1 (Strong Buy) and a Zacks Rank #2 (Buy),
ACTELION LTD (ALIOF): Get Free Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
XENOPORT INC (XNPT): Free Stock Analysis
To read this article on Zacks.com click here.